Abstract
In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.
Author supplied keywords
Cite
CITATION STYLE
Grebely, J., Dore, G. J., Zeuzem, S., Aspinall, R. J., Fox, R., Han, L., … Feld, J. J. (2016). Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials. Clinical Infectious Diseases, 63(11), 1479–1481. https://doi.org/10.1093/cid/ciw579
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
